| 1.05 0.216 (25.9%) | 11-05 12:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.46  |
1-year : | 1.78 |
| Resists | First : | 1.25 |
Second : | 1.53 |
| Pivot price | 1.04 |
|||
| Supports | First : | 0.81 | Second : | 0.67 |
| MAs | MA(5) : | 0.9 |
MA(20) : | 1.08 |
| MA(100) : | 2.17 |
MA(250) : | 5.06 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 14.7 |
D(3) : | 9.2 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 21 | Low : | 0.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LNAI ] has closed above bottom band by 47.7%. Bollinger Bands are 34.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.89 - 0.9 | 0.9 - 0.9 |
| Low: | 0.81 - 0.81 | 0.81 - 0.82 |
| Close: | 0.82 - 0.83 | 0.83 - 0.84 |
A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.
Wed, 05 Nov 2025
Lunai Stock Fluctuates: What’s Next? - StocksToTrade
Wed, 05 Nov 2025
Lunai Bioworks (NASDAQ: LNAI) shows complete pancreatic regression in humanized models - Stock Titan
Fri, 31 Oct 2025
Lunai Bioworks : Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds - MarketScreener
Thu, 30 Oct 2025
Lunai Bioworks receives Nasdaq notice for non-compliance with $35 million market value rule - Investing.com
Thu, 30 Oct 2025
Lunai Bioworks reports promising results from AI platform detecting neurotoxins - Investing.com Nigeria
Fri, 17 Oct 2025
Lunai Bioworks Regains Nasdaq Compliance in October 2025 - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 110.3 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 203 (K) |
| Shares Short P.Month | 111 (K) |
| EPS | -10.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13.6 % |
| Return on Equity (ttm) | -321.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | -0.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|